hit counter

Alzheimer’s Blood Biomarker Models Lose Rule-Out Power Across Cohorts

Editorial card showing Alzheimer's blood biomarker model transfer across cohorts with PET scan and blood assay imagery.

A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved hard: negative predictive value fell from 0.831 inside ADNI to 0.644 when the ADNI-trained model was applied to A4.1 Research Highlights 1,707-person ADNI/A4 test: researchers trained amyloid PET prediction models …

Read more

Lecanemab Blood Biomarkers Rebound Faster Than Amyloid PET After Stopping

Editorial card showing lecanemab maintenance dosing and Alzheimer's blood biomarkers with blood vials, amyloid PET imagery, and biomarker trajectory lines.

Lecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, compared with 12.1 years for amyloid PET signal.1 Research Highlights 0.5-year rebound for Aβ42/40: Bhagunde et al. estimated that half of the Aβ42/40 treatment effect …

Read more

Alzheimer’s Progression AI Model Reaches 0.965 mAUC in TADPOLE Dataset

Editorial card showing Alzheimer progression prediction with longitudinal brain scans, model uncertainty, and TADPOLE cohort data.

A 2026 TADPOLE modeling study reported that a sequential neural process with normalizing flows predicted future Alzheimer diagnostic stage with mAUC 0.965 ± 0.006, ahead of the authors’ earlier sequential-neural-process model at 0.937 ± 0.014.1 The result is a strong benchmark signal for uncertainty-aware disease-progression AI, but it is still retrospective modeling evidence rather than …

Read more

Alpha-Synuclein SAA Detected 95% of Lewy Body Dementia in ALZAN

MHD featured image for alpha-synuclein SAA and Lewy body dementia biomarkers.

A 2026 ALZAN memory-clinic cohort found that cerebrospinal-fluid alpha-synuclein seed amplification assay detected 19 of 20 Lewy body dementia cases, with 95% sensitivity and 93.5% specificity against non-Lewy-body, non-Alzheimer’s controls.1 The same assay was positive in 32 of 203 Alzheimer’s disease patients, which makes the result a co-pathology warning as much as a diagnostic win. …

Read more

Olfactory MRI Radiomics Link pTau217 to Alzheimer’s Cognition

MHD featured image for olfactory MRI radiomics, pTau217, and Alzheimer's disease cognitive impairment.

A 2026 multi-cohort Alzheimer’s disease study found that MRI radiomics from the hippocampus and amygdala linked plasma pTau217 and smell identification to cognitive impairment — with more added cognitive signal than simple regional volume. The result is useful because it points to a possible bridge between blood biomarkers and brain-circuit damage, but it is still …

Read more

Tau Oligomers Disrupted Nuclear Lamina in Alzheimer’s Disease Models

MHD featured image for tau oligomers, nuclear lamina disruption, and Alzheimer's disease models.

A 2026 Acta Neuropathologica study found that oligomeric tau was linked to early nuclear lamina disruption in Alzheimer’s disease tissue, PS19 tauopathy mice, and human induced pluripotent stem cell (iPSC)-derived neurons.1 The strongest claim is mechanistic: tau oligomers appeared to deform the nuclear envelope and disturb chromatin before overt neurodegeneration, but the work does not …

Read more

NDST3 Suppression Restores Lysosome Acidity in Alzheimer’s Mouse Models

MHD featured image for NDST3 suppression and lysosomal acidification in Alzheimer's disease models.

A 2026 mechanistic Alzheimer’s study found that suppressing NDST3 shifted lysosomal pH in APP695Swe neuronal cells from 5.6 back below 5.0, then reduced amyloid-β, MAPT/tau pathology, neuronal injury, and memory deficits in 3xTg-AD mice.1 Research Highlights Lysosome pH moved back down: APP695Swe-overexpressing HT22 cells had lysosomal pH around 5.6, while NDST3 knockdown re-acidified lysosomes to …

Read more